[com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2109]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2114]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=1927]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=1926]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2113]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2110]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=2106]]][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=86882]], camposKey:1470-8736 2024-08-21 Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway10251038, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=86883]], camposKey:1661-6596 2024-08-01 Obesity-Associated Colorectal Cancer00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=87771]], camposKey:2045-2322 2024-01-01 Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=88614]], camposKey:1661-6596 2024-01-01 Mineralocorticoid Receptor and Sleep Quality in Chronic Kidney Disease00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75300]], camposKey:1661-6596 2023-04-01 Involvement of Bcl-2 Family Proteins in Tetraploidization-Related Senescence00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77693]], camposKey:1661-6596 2023-02-01 Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=82858]], camposKey:2234-943X 2023-01-01 Multiomics insights on the onset, progression, and metastatic evolution of breast cancer00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80482]], camposKey:1944-9399 2023-01-01 TiO2 Nanospikes Micro-Areas on Rutile Single Crystal Surfaces Determine Arrangements of Rat Aortic Vascular Smooth Muscle Cells404409, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77677]], camposKey:0007-1188 2022-12-01 The myeloid mineralocorticoid receptor regulates dermal angiogenesis and inflammation in glucocorticoid-induced impaired wound healing52225232, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77694]], camposKey:1661-6596 2022-06-01 Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77695]], camposKey:1664-042X 2022-04-07 Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77681]], camposKey:0022-202X 2020-01-01 Cutaneous Wound Healing in Diabetic Mice Is Improved by Topical Mineralocorticoid Receptor Blockade2230, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77679]], camposKey:0145-8884 2019-12-01 Egg white hydrolysates improve vascular damage in obese Zucker rats by its antioxidant properties00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77678]], camposKey:2045-2322 2019-11-11 Pioglitazone Modulates the Vascular Contractility in Hypertension by Interference with ET-1 Pathway00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77680]], camposKey:0278-6915 2019-11-01 Egg White Hydrolysate: A new putative agent to prevent vascular dysfunction in rats following long-term exposure to aluminum00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77682]], camposKey:0194-911X 2019-02-01 MR (Mineralocorticoid Receptor) Induces Adipose Tissue Senescence and Mitochondrial Dysfunction Leading to Vascular Dysfunction in Obesity458468, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77683]], camposKey:0022-0795 2018-09-01 Mitochondrial oxidative stress in obesity: role of the mineralocorticoid receptor00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77696]], camposKey:2047-9980 2018-06-01 NADPH Oxidase 5 Is a pro-contractile nox isoform and a point of cross-talk for calcium and redox signaling-implications in vascular function00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77684]], camposKey:0300-483X 2017-09-01 Aluminum exposure at human dietary levels promotes vascular dysfunction and increases blood pressure in rats: A concerted action of NAD(P)H oxidase and COX-21021, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77685]], camposKey:0194-911X 2016-09-01 Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by beta-Adrenergic Overstimulation Role of Perivascular Adipose Tissue7260, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77686]], camposKey:0007-1188 2016-05-01 J Role of COX-2-derived PGE(2) on vascular stiffness and function in hypertension15411555, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77687]], camposKey:0007-1188 2015-06-01 Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension31593176, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77688]], camposKey:0022-3565 2015-04-01 Cholesteryl Ester-Transfer Protein Inhibitors Stimulate Aldosterone Biosynthesis in Adipocytes through Nox-Dependent Processes2734, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77689]], camposKey:1932-6203 2014-08-05 Toll-Like Receptor 4 Upregulation by Angiotensin II Contributes to Hypertension and Vascular Dysfunction through Reactive Oxygen Species Production00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77690]], camposKey:0363-6135 2014-06-01 Pioglitazone reduces angiotensin II-induced COX-2 expression through inhibition of ROS production and ET-1 transcription in vascular cells from spontaneously hypertensive rats00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77691]], camposKey:0007-1188 2012-06-01 Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function13031319, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77692]], camposKey:0263-6352 2012-02-01 Peroxisome proliferator-activated receptor-gamma activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress315326, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=77697]], camposKey:0031-6970 2010-01-01 Cyclooxygenase-2, microsomal Prostaglandin e synthase-1 and vascular alterations with hypertension00][][com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=2598]], com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=2599]], com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=2195]]][][com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=1457]]][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64080]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=64080]]][com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=889]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=887]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=886]]][com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=889]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=887]], com.sigma.fs3.argos.domain.gpc.Premis[id=com.sigma.fs3.argos.domain.gpc.GpcPremisPK[ifcactivitat=PRE, ifccomptador=886]]][][][][][][][][GpcPartTribunals[ gpcPartTribunalsPK=GpcPartTribunalsPK[ ifcactivitat=PTR, ifccomptador=922 ] ], GpcPartTribunals[ gpcPartTribunalsPK=GpcPartTribunalsPK[ ifcactivitat=PTR, ifccomptador=929 ] ], GpcPartTribunals[ gpcPartTribunalsPK=GpcPartTribunalsPK[ ifcactivitat=PTR, ifccomptador=926 ] ], GpcPartTribunals[ gpcPartTribunalsPK=GpcPartTribunalsPK[ ifcactivitat=PTR, ifccomptador=924 ] ]][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@1951ab6a, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@19528cd9, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@53f2d07f, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@7695c494, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@628b3bd7, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@6f32471b, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@2a8603aa, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@72efd30a, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@49811b03, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@34f697b7, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@2e7749d0][][][][][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=62345]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=62345]]][][][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@56f250], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c21b5], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c21ae]][][][][][][][]
